Spero Therapeutics (SPRO) Assets Average (2017 - 2026)

Spero Therapeutics (SPRO) has reported Assets Average for 10 consecutive years, with $55.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average fell 20.05% year-over-year to $55.9 million; the trailing twelve-month figure through Jun 2026 stood at $55.9 million (down 20.05% YoY), and the FY2025 full-year result was $89.7 million, down 38.74% from the prior year.
• Assets Average eased to $55.9 million in Q2 2026 per SPRO's latest filing, from $64.0 million in the prior quarter.
• Across five years, Assets Average topped out at $175.0 million in Q1 2024 and bottomed at $55.9 million in Q2 2026.
• Historically, Assets Average has averaged $105.4 million across 5 years, with a median of $103.9 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Assets Average soared 60.8% in 2023, then sank 59.2% in 2025.
• Over 5 years, Assets Average stood at $94.6 million in 2022, then soared by 52.94% to $144.7 million in 2023, then slipped by 15.13% to $122.9 million in 2024, then tumbled by 49.9% to $61.5 million in 2025, then dropped by 9.18% to $55.9 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $55.9 million, $64.0 million, and $61.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.